Literature DB >> 22424158

The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited.

Amelia N Dubovsky1, Sheila Arvikar, Theodore A Stern, Lloyd Axelrod.   

Abstract

BACKGROUND: Glucocorticoids are widely prescribed for a variety of diseases and are known to cause neuropsychiatric as well as somatic side effects.
OBJECTIVE: This article will review the incidence, clinical characteristics, course, and treatment of neuropsychiatric effects of glucocorticoids.
METHODS: We performed a literature review of the neuropsychiatric complications of glucocorticoids using the PubMed database.
RESULTS: The neuropsychiatric effects of glucocorticoids involve affective, behavioral, and cognitive manifestations. Serious neuropsychiatric effects occur in about 6% of patients who receive steroids. Although the effects of glucocorticoids are unpredictable, the administered dose is the most significant risk factor for the development of neuropsychiatric symptoms. Dosage reduction typically results in clinical recovery. Although evidence from controlled trials is sparse, administration of antipsychotics or mood stabilizers may be beneficial in the prevention and treatment of neuropsychiatric effects of steroids.
CONCLUSION: The neuropsychiatric effects of glucocorticoids are more diverse than the often-misleading term "steroid psychosis" suggests. This label should be limited to those patients who are truly psychotic, and specific designations applied to patients with other effects. The adverse neuropsychiatric effects of glucocorticoids remain poorly characterized in the literature (which consists largely of case reports and case series). Reliable risk factors (other than dose) that identify individuals at risk are lacking; guidelines for the prevention of neuropsychiatric effects are not evidence-based. Further controlled clinical studies are needed to elucidate the optimal management of glucocorticoid-induced neuropsychiatric symptoms. Copyright Â
© 2012 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424158     DOI: 10.1016/j.psym.2011.12.007

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  46 in total

Review 1.  Epidemiology and management of neuropsychiatric disorders in Behçet's syndrome.

Authors:  Rosaria Talarico; Laura Palagini; Anna d'Ascanio; Elena Elefante; Claudia Ferrari; Chiara Stagnaro; Chiara Tani; Angelo Gemignani; Mauro Mauri; Stefano Bombardieri; Marta Mosca
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

2.  Do glucocorticoids induce addiction in humans?

Authors:  R Giordano; F Guaraldi; M Mazzoli; E Ghigo
Journal:  J Endocrinol Invest       Date:  2017-03-25       Impact factor: 4.256

Review 3.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 4.  Checkpoint inhibition and melanoma: Considerations in treating the older adult.

Authors:  Claire F Friedman; Jedd D Wolchok
Journal:  J Geriatr Oncol       Date:  2017-05-11       Impact factor: 3.599

Review 5.  Harms from medicines: inevitable, in error or intentional.

Authors:  Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

6.  New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study.

Authors:  Katsuji Nishimura; Masako Omori; Eri Sato; Yasuhiro Katsumata; Takahisa Gono; Yasushi Kawaguchi; Masayoshi Harigai; Hisashi Yamanaka; Jun Ishigooka
Journal:  J Neurol       Date:  2014-08-21       Impact factor: 4.849

7.  Corticosteroid-induced psychiatric disorders: genetic studies are needed.

Authors:  Florence Thibaut
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-09       Impact factor: 5.270

Review 8.  Psychological Considerations in Hematopoietic Stem Cell Transplantation.

Authors:  Hermioni L Amonoo; Christina N Massey; Melanie E Freedman; Areej El-Jawahri; Halyna L Vitagliano; William F Pirl; Jeff C Huffman
Journal:  Psychosomatics       Date:  2019-02-14       Impact factor: 2.386

9.  Secondary psychoses: an update.

Authors:  Matcheri S Keshavan; Yoshio Kaneko
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

10.  Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease.

Authors:  A N Ananthakrishnan; V S Gainer; R G Perez; T Cai; S-C Cheng; G Savova; P Chen; P Szolovits; Z Xia; P L De Jager; S Y Shaw; S Churchill; E W Karlson; I Kohane; R H Perlis; R M Plenge; S N Murphy; K P Liao
Journal:  Aliment Pharmacol Ther       Date:  2013-01-07       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.